BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 38349656)

  • 1. Opportunities for Pharmacogenetic Testing to Guide Dosing of Medications in Youths With Medicaid.
    Tang Girdwood S; Hall M; Antoon JW; Kyler KE; Williams DJ; Shah SS; Orth LE; Goldman J; Feinstein JA; Ramsey LB
    JAMA Netw Open; 2024 Feb; 7(2):e2355707. PubMed ID: 38349656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing Clinical Utility of Pharmacogenetic Testing in the Military Health System.
    Hellwig LD; Turner C; Olsen C; Libbus J; Markos B; Koehlmoos T; Haigney M; De Castro M; Saunders D
    Mil Med; 2024 Jan; 189(1-2):e198-e204. PubMed ID: 37436924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retrospective Review of Pharmacogenetic Testing at an Academic Children's Hospital.
    Roberts TA; Wagner JA; Sandritter T; Black BT; Gaedigk A; Stancil SL
    Clin Transl Sci; 2021 Jan; 14(1):412-421. PubMed ID: 33048453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prescribing Prevalence of Medications With Potential Genotype-Guided Dosing in Pediatric Patients.
    Ramsey LB; Ong HH; Schildcrout JS; Shi Y; Tang LA; Hicks JK; El Rouby N; Cavallari LH; Tuteja S; Aquilante CL; Beitelshees AL; Lemkin DL; Blake KV; Williams H; Cimino JJ; Davis BH; Limdi NA; Empey PE; Horvat CM; Kao DP; Lipori GP; Rosenman MB; Skaar TC; Teal E; Winterstein AG; Owusu Obeng A; Salyakina D; Gupta A; Gruber J; McCafferty-Fernandez J; Bishop JR; Rivers Z; Benner A; Tamraz B; Long-Boyle J; Peterson JF; Van Driest SL;
    JAMA Netw Open; 2020 Dec; 3(12):e2029411. PubMed ID: 33315113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of high-impact gene-drug pairs for pharmacogenetic testing in Alberta, Canada.
    Fan M; Yarema MC; Box A; Hume S; Aitchison KJ; Bousman CA
    Pharmacogenet Genomics; 2021 Feb; 31(2):29-39. PubMed ID: 32826605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of the Implementation of Pharmacogenomic Testing in a Pediatric Tertiary Care Setting.
    Cohn I; Manshaei R; Liston E; Okello JBA; Khan R; Curtis MR; Krupski AJ; Jobling RK; Kalbfleisch K; Paton TA; Reuter MS; Hayeems RZ; Verstegen RHJ; Goldman A; Kim RH; Ito S
    JAMA Netw Open; 2021 May; 4(5):e2110446. PubMed ID: 34037732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prescription Patterns and Relationship to Pharmacogenomics Testing in the Military Health System.
    Selig DJ; Livezey JR; Chin GC; DeLuca JP; Guillory Ii WO; Kress AT; Oliver TO; Por ED
    Mil Med; 2021 Dec; 187(Suppl 1):9-17. PubMed ID: 34967405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of FDA Table of Pharmacogenetic Associations and Clinical Pharmacogenetics Implementation Consortium guidelines.
    Pritchard D; Patel JN; Stephens LE; McLeod HL
    Am J Health Syst Pharm; 2022 Jun; 79(12):993-1005. PubMed ID: 35230418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ADME Gene-Related Pharmacogenomic Labeling of FDA-Approved Drugs: Comparison with Clinical Pharmacogenetics Implementation Consortium (CPIC) Evidence Levels.
    Deb S; Hopefl R; Reeves AA; Cvetkovic D
    Medicines (Basel); 2024 Feb; 11(3):. PubMed ID: 38535119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of exposure to pharmacogenetic drugs by the Saudis treated at the health care centers of the Ministry of National Guard.
    Alshabeeb MA; Alyabsi M; Paras B
    Saudi Pharm J; 2022 Aug; 30(8):1181-1192. PubMed ID: 36164570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of population-level pharmacogenetic actionability in Alabama.
    Davis BH; Williams K; Absher D; Korf B; Limdi NA
    Clin Transl Sci; 2021 Nov; 14(6):2327-2338. PubMed ID: 34121327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating the frequency and the impact of pharmacogenetic alleles in an ancestrally diverse Biobank population.
    Verma SS; Keat K; Li B; Hoffecker G; Risman M; ; Sangkuhl K; Whirl-Carrillo M; Dudek S; Verma A; Klein TE; Ritchie MD; Tuteja S
    J Transl Med; 2022 Nov; 20(1):550. PubMed ID: 36443877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An analysis of allele, genotype and phenotype frequencies, actionable pharmacogenomic (PGx) variants and phenoconversion in 5408 Australian patients genotyped for CYP2D6, CYP2C19, CYP2C9 and VKORC1 genes.
    Mostafa S; Kirkpatrick CMJ; Byron K; Sheffield L
    J Neural Transm (Vienna); 2019 Jan; 126(1):5-18. PubMed ID: 30191366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fetal pharmacogenomics: A promising addition to complex neonatal care.
    Raymond M; Critchlow E; Rice SM; Wodoslawsky S; Berger SI; Hegde M; Empey PE; Al-Kouatly HB
    Mol Genet Metab; 2022; 137(1-2):140-145. PubMed ID: 36029725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of drugs with pharmacogenomics (PGx)-based dosing guidelines in a Danish cohort of persons with chronic kidney disease, both on dialysis and not on dialysis: Perspectives for prescribing optimization.
    Westergaard N; Baltzer Houlind M; Christrup LL; Juul-Larsen HG; Strandhave C; Olesen AE
    Basic Clin Pharmacol Toxicol; 2024 Apr; 134(4):531-542. PubMed ID: 38308569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multisite evaluation of institutional processes and implementation determinants for pharmacogenetic testing to guide antidepressant therapy.
    Tuteja S; Salloum RG; Elchynski AL; Smith DM; Rowe E; Blake KV; Limdi NA; Aquilante CL; Bates J; Beitelshees AL; Cipriani A; Duong BQ; Empey PE; Formea CM; Hicks JK; Mroz P; Oslin D; Pasternak AL; Petry N; Ramsey LB; Schlichte A; Swain SM; Ward KM; Wiisanen K; Skaar TC; Van Driest SL; Cavallari LH; Bishop JR;
    Clin Transl Sci; 2022 Feb; 15(2):371-383. PubMed ID: 34562070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determining the potential clinical value of panel-based pharmacogenetic testing in patients with chronic pain or gastroesophageal reflux disease.
    Elchynski AL; Cicali EJ; Ferrer Del Busto MC; Hamilton A; Chang KL; Schmidt SO; Weiner B; Davis R; Estores D; Max Smith D; Wiisanen K; Johnson JA; Cavallari LH
    Pharmacogenomics J; 2021 Dec; 21(6):657-663. PubMed ID: 34075203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence of Exposure of Patients in the United States to Multiple Drugs for Which Pharmacogenomic Guidelines Are Available.
    Samwald M; Xu H; Blagec K; Empey PE; Malone DC; Ahmed SM; Ryan P; Hofer S; Boyce RD
    PLoS One; 2016; 11(10):e0164972. PubMed ID: 27764192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Projected Prevalence of Actionable Pharmacogenetic Variants and Level A Drugs Prescribed Among US Veterans Health Administration Pharmacy Users.
    Chanfreau-Coffinier C; Hull LE; Lynch JA; DuVall SL; Damrauer SM; Cunningham FE; Voight BF; Matheny ME; Oslin DW; Icardi MS; Tuteja S
    JAMA Netw Open; 2019 Jun; 2(6):e195345. PubMed ID: 31173123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of Pharmacogenomics on Pediatric Psychotropic Medication Prescribing in an Ambulatory Care Setting.
    Tonti E; Lee YM; Gruenke N; Ferren J; Stutzman DL
    J Child Adolesc Psychopharmacol; 2024 Feb; 34(1):52-60. PubMed ID: 38377527
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.